This is the authors' abstract. We don't add key points for this paper.
Breast cancer is a leading cause of morbidity and mortality among women globally. Tumor markers play a critical role in diagnosis, treatment monitoring, and prognosis. This review focuses on Glutathione S-transferase (GST), particularly its pi isoenzyme (GSTP1), as well as tumor markers CA15-3 and HE4, in breast cancer patients before and after treatment. These markers are crucial for understanding disease progression, assessing treatment efficacy, and developing therapeutic strategies. Glutathione S-transferase, particularly its pi isoenzyme, along with tumor markers CA15-3 and HE4, holds significant promise in the management of breast cancer. Their combined evaluation before and after treatment could provide crucial insights into disease progression, treatment response, and potential recurrence.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hawale et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: